Pharma Q3: Eris, IPCA Soar, Blue Jet Profit Jumps 59.6% Amid Revenue Dip
CCNBC Awaaz•13-02-2026, 14:20
Pharma Q3: Eris, IPCA Soar, Blue Jet Profit Jumps 59.6% Amid Revenue Dip
- •Eris Lifesciences and IPCA Laboratories reported strong Q3 growth in profit and revenue.
- •Eris Lifesciences' consolidated profit rose 19% to ₹100 crore, with revenue increasing to ₹807 crore.
- •IPCA Laboratories saw consolidated profit climb from ₹248 crore to ₹326 crore, and revenue reached ₹2392 crore.
- •Blue Jet Healthcare's net profit surged 59.6% to ₹99 crore, despite a 39.6% revenue decrease and significant EBITDA fall.
- •Alkem Laboratories recorded YoY growth in profit and revenue, but faced a slight EBITDA margin decline and a ₹53 crore one-time expense.